Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1907601 Target Snapshot

Cyclin-dependent kinase 4/cyclin D1 · PROTEIN COMPLEX · Homo sapiens

2,711Compounds
393Assays
6Approved Drugs
2,682.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Cyclin-dependent kinase 4/cyclin D1 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P11802. Start with breast cancer, then reuse UniProt P11802 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P11802 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
breast cancer

Cyclin-dependent kinase 4/cyclin D1 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include PALBOCICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 4/cyclin D1 as ChEMBL target CHEMBL1907601, mapped to UniProt P11802. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 4/cyclin D1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1907601
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P11802
Cyclin-dependent kinase 4
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-dependent kinase 4/cyclin D1 is the right protein anchor across sources, using UniProt P11802 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCyclin-dependent kinase 4
UniProt AccessionP11802
Component TypeProtein
Sequence Length303 aa

Cyclin-dependent kinase 4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cyclin-dependent kinase 4/cyclin D1, mapped to UniProt P11802. ChEMBL maps the protein component as Cyclin-dependent kinase 4. Sequence length is 303 aa.

Mapped IDP11802
Review nameCyclin-dependent kinase 4/cyclin D1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Cyclin-dependent kinase 4/cyclin D1 shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
breast carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
breast neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
HER2 Positive Breast Carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugPALBOCICLIB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include PALBOCICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
4
Phase III
22
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC502,180.0
KI495.0
EC502.0
KD5.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5272948 10.33 Ki 0.047 Preclinical
CHEMBL5198209 10.0 IC50 0.1 Preclinical
CHEMBL5266837 10.0 Ki 0.1 Preclinical
CHEMBL5749795 10.0 Ki 0.1 Preclinical
CHEMBL5783305 10.0 Ki 0.1 Preclinical
CHEMBL5786491 10.0 Ki 0.1 Preclinical
CHEMBL5795283 10.0 Ki 0.1 Preclinical
CHEMBL5799855 10.0 Ki 0.1 Preclinical
CHEMBL5876670 10.0 Ki 0.1 Preclinical
CHEMBL5882519 10.0 Ki 0.1 Preclinical
Distribution

pChEMBL Value Distribution

115
5.0
129
5.5
195
6.0
233
6.5
273
7.0
280
7.5
262
8.0
187
8.5
166
9.0
43
9.5
pChEMBL
Approved Drugs

Approved Drugs

TRILACICLIB
CHEMBL3894860
Approved 2021
ABEMACICLIB
CHEMBL3301610
Approved 2017
RIBOCICLIB
CHEMBL3545110
Approved 2017
PALBOCICLIB
CHEMBL189963
Approved 2015
Assay Landscape

Assay Landscape

393
Total Assays
1,893
Tested Compounds
2
Assay Types
Binding — 392 assays, 1,893 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 294 1,569 7.2
cell-based format 63 234 6.2
assay format 31 84 7.0
single protein format 4 6 5.8
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine